The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab

Clinical Nutrition

Volumn 30, Issue 1, 2011, Pages 86-91

  Vadan, Roxana ^a   Gheorghe, Liliana Simona ^a   Constantinescu, Alexandrina ^a   Gheorghe, Cristian ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Crohn's disease; Infliximab; Malnutrition; Nutritional status; TNF

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CROHN DISEASE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; MALE; MALNUTRITION; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; REMISSION; WEIGHT GAIN;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; BODY MASS INDEX; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MALNUTRITION; MIDDLE AGED; NUTRITIONAL STATUS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 79451470968     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2010.07.019     Document Type: Article

References (27)

1. Sasaki M., Johtatsu T., Kurihara M., Iwakawa H., Tanaka T., Tsujikawa T., et al. Energy metabolism in Japanese patients with Crohn's disease. J Clin Biochem Nutr 2010, 46(1):68-72.
2. Aghdassi E., Wendland B.E., Stapleton M., Raman M., Allard J.P. Adequacy of nutritional intake in a Canadian population of patients with Crohn's disease. J Am Diet Assoc 2007, 107(9):1575-1580.
3. Filippi J., Al-Jaouni R., Wiroth J.B., Hébuterne X., Schneider S.M. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 2006, 12(3):185-191.
4. Sousa Guerreiro C., Cravo M., Costa A.R., Lourdes Tavares A.M., Moura-Santos P., MarquesVidal P., et al. A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. Am J Gastroenterol 2007, 102(11):2551-2556.
5. Van Gossum A., Cabre E., Hébuterne X., Jeppesen P., Krznaric Z., Messing B., et al. ESPEN guidelines on parenteral nutrition: gastroenterology. Clin Nutr 2009, 28(4):415-427.
6. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997, 337(15):1029-1035. Crohn disease cA2 Study Group.
7. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002, 359(9317):1541-1549. ACCENT I Study Group.
8. D'Haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116(5):1029-1034.
9. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. Gastroenterology 1976, 70(3):439-444. National Cooperative Crohn's Disease Study.
10. Buzby G.P., Knox L.S., Crosby L.O., Eisenberg J.M., Haakenson C.M., McNeal G.E., et al. Study protocol: a randomized clinical trial of total parenteral nutrition in malnourished surgical patients. Am J Clin Nutr 1988, 47(Suppl. 2):366-381.
11. Griffiths A.M., Nguyen P., Smith C., MacMillan J.H., Sherman P.M. Growth and clinical course of children with Crohn's disease. Gut 1993, 34(7):939-943.
12. Savage M., Beattie R., Camacho-Hubner C., Walker-Smith J.A., Sanderson I.R. Growth in Crohn's disease. Acta Paediatr 1999, 88(428):89-92. Suppl.
13. Nguyen G.C., Munsell M., Harris M.L. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008, 14(8):1105-1111.
14. Buzby G.P., Williford W.O., Peterson O.L., Crosby L.O., Page C.P., Reinhardt G.F., et al. A randomized clinical trial of total parenteral nutrition in malnourished surgical patients: the rationale and impact of previous clinical trials and pilot study on protocol design. Am J Clin Nutr 1988, 47(2):357-365. Suppl.
15. Naber T.H., Schermer T., de Bree A., Nusteling K., Eggink L., Kruimel J.W., et al. Prevalence of malnutrition in nonsurgical hospitalized patients and its association with disease complications. Am J Clin Nutr 1997, 66(5):1232-1239.
16. Capristo E., Addolorato G., Mingrone G., Greco A.V., Gasbarrini G. Effect of disease localization on the anthropometric and metabolic features of Crohn's disease. Am J Gastroenterol 1998, 93(12):2411-2419.
17. Marcil V., Bucionis V., Bitton A., Szilagy A., Serban D., Levy E., et al. Malnutrition in adults and children with IBD: is there a difference?. Am J Gastroenterol 2009, 104(Suppl. 3):S550.
18. Capristo E., Mingrone G., Addolorato G., Greco A.V., Gasbarrini G. Metabolic features of inflammatory bowel disease in a remission phase of the disease activity. J Intern Med 1998, 243(5):339-347.
19. Burnham J.M., Shults J., Semeao E., Foster B.J., Zemel B.S., Stallings V.A., et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 2005, 82(2):413-420.
20. Argilés J.M., López-Soriano J., Busquets S., López-Soriano F.J. Journey from cachexia to obesity by TNF. FASEB J 1997, 11(10):743-751.
21. Spiegelman B.M., Flier J.S. Obesity and the regulation of energy balance. Cell 2001, 104(4):531-543.
22. Franchimont D., Roland S., Gustot T., Quertinmont E., Toubouti Y., Gervy M.C., et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005, 90(6):3510-3516.
23. Fawcett R.L., Waechter A.S., Williams L.B., Zhang P., Louie R., Jones R., et al. Tumor necrosis factor-α inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humans. J Clin Endocrinol Metab 2000, 85(2):530-535.
24. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Kouroumalis E.A. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2007, 19(9):789-794.
25. Derdemezis C.S., Filippatos T.D., Voulgari P.V., Tselepis A.D., Drosos A.A., Kiortsis D.N. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol 2009, 23(5):595-600.
26. Gisondi P., Cotena C., Tessari G., Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008, 22(3):341-344.
27. Briot K., Gossec L., Kolta S., Dougados M., Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008, 35(5):855-861.